Domestic Dual-Target CAR-T Therapy KQ-2003 Secures Two Overseas Licensing Deals Within Three Months

According to the terms of the agreement, Novatim will receive an upfront payment and milestone payments during the R&D, registration, and commercialization stages. In addition, Novatim will also be entitled to tiered royalties in the high single-digit to double-digit percentage range based on the net sales of KQ-2003 within the licensed territory.

KQ-2003 is an innovative therapy developed by Novatim based on an enhanced dual-target CAR-T platform. Through parallel structural design and signal domain optimization, it significantly improves the persistence and anti-tumor activity of CAR-T cells while reducing the risk of relapse associated with traditional CAR-T therapies.

Its core advantages include: excellent efficacy, safety advantages, and cost competitiveness, currently inRelapsed/Refractory Multiple Myeloma（rrMM）and POEMS Syndrome...have achieved exciting efficacy in pivotal clinical trials.

KQ-2003 is currently in Phase I/IIa clinical trials in China.In July this year, Erigen has obtained the rights for this product outside of Greater China.(Excluding India, Turkey, Russia)Development and Commercialization Authorization。

According to the terms of the cooperation, Novatim will obtain$15 millionRecent development milestone payments, with eligibility for a total amount up to$1.32 billionmilestone payments during the R&D, registration, and commercialization stages. In addition, Novatim will also receive up to a certain percentage of net sales revenue from KQ-2003 in the licensed region.$800 millionSales split.

This new authorization further confirms the global recognition of the development potential and market value of KQ-2003. Leveraging clinical trials in India and the fast-track market entry mechanism, KQ-2003Expected to be the first to achieve market launch in India, providing new treatment options for local patients and accelerating Novatim's commercial returns.